What's in Exelixis's pipeline?

Exelixis has 14 drugs in our index: 2 marketed, 0 filed, 3 in Phase 3, 1 in Phase 2, 8 in Phase 1.

Which companies overlap with Exelixis's portfolio?

Top competitors by shared drug class: H. Lee Moffitt Cancer Center and Research Institute, Pfizer, Novartis, Bayer, Children's Hospital of Fudan University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/exelixis.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Exelixis — Portfolio Competitive Intelligence Brief

Exelixis (EXEL) pipeline: 2 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

EXEL (NASDAQ) 2 marketed 0 filed 3 Phase 3 1 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Cometriq	Cabometyx	marketed	Kinase Inhibitor	Vascular endothelial growth factor receptor 2	Oncology	2012-01-01
Cometriq	CABOZANTINIB	marketed	Kinase Inhibitor	Vascular endothelial growth factor receptor 2	Oncology	2012-01-01
Everolimus (Afinitor) tablets	Everolimus (Afinitor) tablets	phase 3	mTOR inhibitor	mTOR (mTORC1)	Oncology
Cabozantinib tablets	Cabozantinib tablets	phase 3	Multi-targeted tyrosine kinase inhibitor	MET, VEGFR2, AXL	Oncology
XL184	XL184	phase 3	Multi-targeted tyrosine kinase inhibitor	MET, VEGFR2, RET	Oncology

Therapeutic area mix

Oncology · 5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2026-08-14 — Cometriq · 7579473 · US
2030-01-15 — Cometriq · 11091439 · US
2030-01-15 — Cometriq · 11098015 · US
2030-01-15 — Cometriq · 11091440 · US
2030-10-08 — Cometriq · 8877776 · US
2031-07-18 — Cometriq · 10034873 · US
2031-07-18 — Cometriq · 10039757 · US
2032-02-10 — Cometriq · 11298349 · US
2032-02-10 — Cometriq · 9717720 · US
2033-07-09 — Cometriq · 9724342 · US

Competitive overlap (companies sharing drug classes)

H. Lee Moffitt Cancer Center and Research Institute · 2 shared drug classes
Pfizer · 2 shared drug classes
Novartis · 2 shared drug classes
Bayer · 1 shared drug class
Children's Hospital of Fudan University · 1 shared drug class
Chong Kun Dang Pharmaceutical · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
GWT-TUD GmbH · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Exelixis:

Cite this brief

Drug Landscape (2026). Exelixis — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/exelixis. Accessed 2026-05-14.